{"entity":{"id":"nct01872260","kind":"trial","name":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer","aka":[],"tldr":"A phase 1/2 trial of LEE011 in advanced solid tumours, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer is a phase 1/2 interventional study registered as NCT01872260 by Novartis Pharmaceuticals, with 255 participants enrolled, started 2013-10-22 and due to reach its primary completion in 2027-02-26. Interventions recorded: LEE011, Letrozole and BYL719.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01872260","url":"https://clinicaltrials.gov/study/NCT01872260"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT01872260","phase":"1/2","setting":"A Phase Ib/II, Multicenter Study of the Combination of LEE011 and BYL719 With Letrozole in Adult Patients With Advanced ER+ Breast Cancer","sponsor":"Novartis Pharmaceuticals","enrolled":255,"outcomes":[]},"route":"/trials/nct01872260/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}